RTX-224 Monotherapy in Patients With Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Cutaneous Melanoma|Head and Neck Squamous Cell Carcinoma|Urothelial Carcinoma|TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: RTX-224
Sponsor: Rubius Therapeutics